Endocrine system disorder
MONDO:0005151A disease involving the endocrine system.
Also known as: disease of endocrine system, disease or disorder of endocrine system, disorder of endocrine system, endocrine disease, endocrine disorder, endocrine system disease, endocrine system disease or disorder, endocrine system disorder
11776 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 4508 trials in this tab.
-
Can donor immune cells be engineered to fight blood cancer?
⭐️ CURE ⭐️ Recruiting nowThis trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
A made-to-order DNA vaccine takes aim at liver cancer's return
⭐️ VACCINE ⭐️ Recruiting nowThis phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…
Phase: PHASE2 • Sponsor: Geneos Therapeutics • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 19, 2026 10:00 UTC
-
Liver pump chemotherapy may boost survival in advanced colorectal cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Whey protein before meals may tame blood sugar spikes in seniors with diabetes
Disease control Recruiting nowThis study tests whether drinking whey protein before meals can help adults aged 75-90 with type 2 diabetes keep their blood sugar in a healthy range. Participants will take whey protein or a placebo before each meal for a week, and their blood sugar will be tracked continuously.…
Phase: NA • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New pill plus chemo takes on deadly pancreatic cancer in huge trial
Disease control Recruiting nowThis phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New obesity drug ARO-INHBE enters human trials
Disease control Recruiting nowThis study tests an experimental drug called ARO-INHBE in 180 adults with obesity, some of whom also have type 2 diabetes. The drug is given as a shot under the skin, either alone or combined with the existing weight-loss drug tirzepatide. The main goal is to check safety and how…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New smart bomb for liver cancer: radiation drug targets tumors only
Disease control Recruiting nowThis early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, so…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New hope for rare gut disease? drug trial launches for APECED enteritis
Disease control Recruiting nowThis phase 2 trial tests a drug called emapalumab in 10 people with APECED, a rare disease where the immune system attacks the body. The drug aims to reduce gut inflammation (enteritis) that causes severe symptoms. Participants receive 7 IV doses over 6 months, and researchers tr…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Can a new injection tame chronic hepatitis b?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called HECN30227, given as an injection, in healthy volunteers and in people with chronic hepatitis B. The study aims to assess the drug's safety, how the body processes it, and its potential to reduce the virus. Participa…
Phase: PHASE1 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New hope for tough pancreatic cancers: drug combo aims to shrink tumors before surgery
Disease control Recruiting nowThis early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…
Phase: PHASE1 • Sponsor: PanTher Therapeutics • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New radiation approach before surgery for rare adrenal cancer
Disease control Recruiting nowThis early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New hope for pancreatic cancer: experimental combo trial launches
Disease control Recruiting nowThis study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New drug combo aims to shrink Hard-to-Treat neuroendocrine tumors
Disease control Recruiting nowThis study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Second dose of targeted radiation may outperform standard drugs for stubborn gut tumors
Disease control Recruiting nowThis study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Can a diabetes drug rev up muscle power?
Disease control Recruiting nowThis trial asks whether empagliflozin, metformin, or a combination of both can improve how muscles produce energy and respond to blood flow in people newly diagnosed with type 2 diabetes. About 54 men with type 2 diabetes will be randomly assigned to one of three groups: empaglif…
Phase: PHASE4 • Sponsor: University Medical Centre Ljubljana • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Hepatitis b breakthrough? new drug AHB-137 shows promise in Long-Term Follow-Up
Disease control Recruiting nowThis study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves witho…
Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Radioactive therapy targets rare tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests a radioactive drug called Lu-177-DOTATATE in 130 adults with rare adrenal or neck tumors that cannot be surgically removed. The drug is given four times over about 8 months, and researchers track how long the cancer stays under control. The goal is to see…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Gene test could tailor chemo doses for rare cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cispl…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New combo therapy targets tough lung cancer in early trial
Disease control Recruiting nowThis study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Can adding interferon boost immunotherapy against liver cancer?
Disease control Recruiting nowThis study tests whether adding pegylated interferon alpha-2b to standard targeted immunotherapy can help people with advanced liver cancer caused by hepatitis B. The trial enrolls adults with unresectable, intermediate-to-advanced disease who are already on antiviral therapy. Pa…
Phase: NA • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New drug combo aims to tame hepatitis b virus
Disease control Recruiting nowThis study tests two drugs, VIR-2218 and peginterferon, in 50 adults with mild chronic hepatitis B. The goal is to lower the virus level in the blood and improve the body's immune response. Participants receive injections for 6 months and are followed for over 2 years, including …
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New drug HWK-016 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New drug combo aims to shrink liver tumors in First-Line patients
Disease control Recruiting nowThis study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…
Phase: PHASE1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Cutting scans, keeping safety: a new streamlined approach to liver cancer treatment
Disease control Recruiting nowThis trial tests a streamlined version of radioembolization, a treatment that delivers tiny radioactive beads directly to liver tumors. The standard procedure requires extra imaging beforehand to check for radiation leakage to the lungs, which can delay treatment. For patients wi…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Could a cancer drug slow bile duct tumors?
Disease control Recruiting nowThis study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New radioactive drug targets Hard-to-Treat gut and adrenal tumors
Disease control Recruiting nowThis study tests a new radioactive drug, [212Pb]VMT-alpha-NET, in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paragangliomas that have already been treated with radiation therapy. The drug is designed to attach to a protein on the surface of th…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
Streamlined liver cancer treatment tested in new study
Disease control Recruiting nowThis study tests a faster version of radioembolization for people with small liver cancers (5 cm or less). Normally, doctors do a pre-treatment scan to check for lung risks, but this trial skips that step for carefully selected patients. The goal is to see if the simplified appro…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New app aims to help diabetes patients take control at home
Disease control Recruiting nowThis study tests whether a mobile health app can help people with type 2 diabetes better manage their condition. About 388 adults in Italy will use the app to track blood sugar, diet, and activity, and communicate with their care team. The goal is to see if app users have better …
Phase: NA • Sponsor: Marche Region Regional Health Agency • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
One-Day fix for big liver tumors? new study tests Same-Day radiation
Disease control Recruiting nowThis study tests whether people with large liver cancer (over 5 cm) can get their entire radioembolization treatment in a single day. Normally, planning scans and treatment are done on separate days. The procedure involves injecting tiny radioactive beads into the liver's blood s…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New drug targets cancer spread in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New drug NRM-823 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated Aug 19, 2026 10:00 UTC
-
New hope for tough lung cancer: targeted pill alisertib under study
Disease control Recruiting nowThis Phase 2 trial tests the drug alisertib in 120 people with extensive stage small cell lung cancer that has worsened after standard treatments like chemotherapy and immunotherapy. The goal is to see if alisertib can shrink tumors or slow the disease, and to identify which pati…
Phase: PHASE2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for advanced liver cancer: radiation boosts immunotherapy in major trial
Disease control Recruiting nowThis phase 3 trial is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs (atezolizumab and bevacizumab) alone versus the same drugs plus targeted radiation (SBRT). The goal is to see if adding radiation helps pa…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a diabetes drug fix liver energy problems in fatty liver disease?
Disease control Recruiting nowThis study looks at whether the diabetes drug pioglitazone can improve how the liver processes energy in people with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Researchers will measure liver mitochondrial function using special tracers before and after 16 weeks…
Phase: PHASE4 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could existing cancer drugs tackle rare tumors? new trial aims to find out
Disease control Recruiting nowThis trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug cocktail targets rare bile duct cancer
Disease control Recruiting nowThis study tests whether combining three drugs—pemigatinib, atezolizumab, and bevacizumab—can help control advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). About 25 adults whose cancer has not responded to other treatments will take part. The main goal…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy aims to boost radiation for tough pancreatic tumors
Disease control Recruiting nowThis early-phase trial tests a drug called XER-001 (a form of amifostine given through a tube into the small intestine) combined with precise radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 36 participa…
Phase: PHASE1, PHASE2 • Sponsor: Xerient Pharma • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for rare lung cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New trial tests smarter radiation to protect memory in lung cancer patients
Disease control Recruiting nowThis phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for tough lung cancer: targeted drug ZL-1310 enters final testing
Disease control Recruiting nowThis Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…
Phase: PHASE3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Last-Resort drug access opens for advanced pancreatic cancer patients
Disease control AVAILABLEThis program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a stronger radiation blast tame pancreatic cancer?
Disease control Recruiting nowThis phase III trial tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The study compares higher-dose radiation to standard care (more chemo, observat…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy aims to buy more time for bile duct cancer patients
Disease control Recruiting nowThis study compares standard chemotherapy (gemcitabine and oxaliplatin) alone versus the same drugs plus a liver-directed chemotherapy (HAI FUDR/dexamethasone) in people with bile duct cancer that has spread within the liver but cannot be removed surgically. About 164 adults with…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New pill targets tough pancreatic cancer mutation
Disease control Recruiting nowThis study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Immune cells retrained to hunt ovarian cancer in new trial
Disease control Recruiting nowThis phase 1 trial investigates a new treatment for advanced ovarian cancer that has stopped responding to platinum chemotherapy. The therapy uses a patient's own immune cells, called T cells, which are genetically modified in a lab to recognize and attack a protein called TAG72 …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New diabetes drug HM15275 enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called HM15275 in people with type 2 diabetes. The goal is to see if it can lower blood sugar levels (HbA1c) safely over 36 weeks. About 180 adults who manage their diabetes with diet, exercise, or metformin will take part. Half will get the drug, …
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New monthly shot could help people with obesity shed pounds
Disease control Recruiting nowThis study tests a once-monthly injection called berobenatide to help adults with overweight or obesity lose weight. About 954 participants will receive either the drug or a placebo for 20 months. The goal is to see if the drug is safe and effective for weight loss, including in …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could family clinics cure hepatitis c as well as specialists?
Disease control Recruiting nowThis trial tests whether treating hepatitis C in primary care clinics, with non-specialist doctors, works as well as the standard specialist care in Brazil. It also evaluates the use of rapid tests and self-testing to find more people with the infection. The goal is to see if a s…
Phase: PHASE4 • Sponsor: Oswaldo Cruz Foundation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug SIM0505 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…
Phase: PHASE1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise for rare cervical cancer
Disease control Recruiting nowThis study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy and radiation can help women with a rare and aggressive type of cervical cancer called small cell neuroendocrine carcinoma. About 45 women with early to advanced stages of the disease…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Immune cell boost plus targeted procedure shows promise for inoperable liver tumors
Disease control Recruiting nowThis Phase 2 trial tests whether adding a special immune cell infusion (GKL-006) to a standard procedure that blocks blood flow to tumors (TACE) can shrink liver cancers that cannot be removed by surgery. About 48 adults with unresectable hepatocellular carcinoma will receive the…
Phase: PHASE2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo aims to fight tough lung cancer
Disease control Recruiting nowThis study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can adding radiation at the right time boost immunotherapy for aggressive lung cancer?
Disease control Recruiting nowThis study is exploring whether giving radiotherapy at the same time as immunotherapy and chemotherapy, versus giving it after, works better as a first treatment for extensive-stage small cell lung cancer. The trial will enroll about 60 adults with this advanced cancer. Participa…
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a simple patch stop diabetes device skin woes?
Disease control Recruiting nowThis trial tests whether a silicone-based or a hydrocolloid patch placed under insulin pumps or glucose monitors can prevent contact dermatitis from coming back in children aged 2-18. Participants will use different patches and attend visits for skin exams, ultrasounds, and quest…
Phase: NA • Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Tailored radiation: new trial aims to personalize cancer treatment
Disease control Recruiting nowThis study tests personalized radiotherapy approaches for people with lung cancer, brain metastases, or other solid tumors. It aims to see if adapting radiation based on how a patient responds is safe and effective. About 45 adults will participate, receiving either extra radiati…
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo takes on tough lung cancer
Disease control Recruiting nowThis study tests a new medicine called PF-08634404 given with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The trial has two parts: first checking safety, then comparing the new combo to an approved treatment (atezoli…
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for liver cancer: pfizer tests experimental drug
Disease control Recruiting nowThis study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could a simple questionnaire transform diabetes consultations?
Disease control Recruiting nowThis trial tests whether using a diabetes-specific questionnaire during annual check-ups can improve the quality of care for people with type 2 diabetes. About 2,000 adults with type 2 diabetes from 30 general practices in Denmark will take part. Half of the practices will use th…
Phase: NA • Sponsor: University of Aarhus • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New mRNA vaccine aims to stop ovarian Cancer's return
Disease control Recruiting nowThis early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…
Phase: PHASE1 • Sponsor: Epitopea Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New lung cancer combo aims to outperform current standard in consolidation therapy
Disease control Recruiting nowThis study tests whether a new drug combination (BMS-986489) works better than the current standard (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults whose cancer hasn't spread widely will be randomly assigned to o…
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could probiotics help ovarian cancer patients on chemo?
Disease control Recruiting nowThis study tests whether taking probiotic supplements can improve the gut and vaginal microbiome in women with advanced or recurrent ovarian cancer who are receiving platinum-based chemotherapy. About 161 participants will be randomly assigned to receive either probiotics or a pl…
Phase: EARLY_PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new injection tame chronic hepatitis b?
Disease control Recruiting nowThis early-stage trial is evaluating an investigational drug called ACT201, given as an injection, to see if it is safe and tolerable. The study first tests single and multiple doses in healthy volunteers, then moves to people with chronic hepatitis B whose virus is already suppr…
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug aims to tame tumor-triggered low blood sugar in rare cancer patients
Disease control Recruiting nowThis study tests a new medicine called ersodetug for people whose tumors cause dangerously low blood sugar that standard treatments can't control. About 16 adults with insulin-producing tumors will receive the drug alongside their usual care. The main goal is to see if ersodetug …
Phase: PHASE3 • Sponsor: Rezolute • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New weekly shot could help obese diabetics shed pounds and control blood sugar
Disease control Recruiting nowThis Phase 3 trial is testing a new weekly injection called enicepatide for weight loss in 1600 people who are obese or overweight and also have type 2 diabetes. The drug works by mimicking natural hormones that help control appetite and blood sugar. Participants will receive eit…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to boost immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Free veggies and cooking classes aim to tame diabetes in pregnancy
Disease control Recruiting nowThis study tests a program that delivers fresh produce to the homes of pregnant women with type 1 or 2 diabetes who also struggle to afford healthy food. Participants also get group classes on diabetes, nutrition, and cooking, plus help finding other resources. The goal is to see…
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced liver cancer: immunotherapy cocktails under study
Disease control Recruiting nowThis clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a daily pill tame obesity and type 2 diabetes?
Disease control Recruiting nowThis trial is testing an experimental once-daily pill called ASC30 in adults who are overweight or have obesity and also have type 2 diabetes. The study aims to see if ASC30 can help with long-term weight loss and improve blood sugar control compared to a placebo. Participants wi…
Phase: PHASE3 • Sponsor: Ascletis Pharma (China) Co., Limited • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to fight aggressive lung cancer
Disease control Recruiting nowThis study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a breast cancer drug help women with PCOS ovulate?
Disease control Recruiting nowThis study tests whether exemestane, a drug typically used for breast cancer, can help women with polycystic ovary syndrome (PCOS) ovulate. Participants take either a low or high dose of exemestane or a placebo for 5 to 10 days. Researchers track ovulation through blood tests and…
Phase: PHASE1 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a common antioxidant rescue failing livers?
Disease control Recruiting nowThis trial tests whether adding N-acetylcysteine (NAC) to standard care improves survival in adults with acute liver failure not caused by acetaminophen. Sixty-two patients will be randomly assigned to receive NAC or standard care alone. The study tracks survival at 28 days, hosp…
Phase: NA • Sponsor: King Edward Medical University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill plus chemo aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…
Phase: PHASE3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can radiation kickstart the immune system against stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Psoriasis drug may be safe for patients with fatty liver
Disease control Recruiting nowThis study looks at how long adults with plaque psoriasis and a common liver condition called MASLD (fatty liver disease) continue taking the drug secukinumab. Researchers will review medical records from several Spanish hospitals to track treatment duration and changes in liver …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Fish oil treatment tested for kids with liver damage from IV nutrition
Disease control Recruiting nowThis study is testing the safety of Omegaven, a fish oil-based fat emulsion, in 40 children under 18 who have developed liver problems (cholestasis) from long-term IV nutrition. The main goal is to see how many children develop essential fatty acid deficiency during at least 8 we…
Sponsor: Fresenius Kabi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Gene therapy takes on hepatitis b: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarr…
Phase: PHASE1 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could alternating chemo drugs boost survival in biliary cancer?
Disease control Recruiting nowThis phase 2 trial tests whether alternating between two chemotherapy regimens (mFOLFOX and mFOLFIRI) works better than using just one (mFOLFOX) as a second-line treatment for advanced biliary tract cancer. The study will enroll 130 adults whose cancer has progressed after first-…
Phase: PHASE2 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Pregnant women with hepatitis c get new hope in drug trial
Disease control Recruiting nowThis study is testing the safety and drug levels of glecaprevir/pibrentasvir, a hepatitis C treatment, in 30 pregnant women with or without HIV. The goal is to see how the drug works during pregnancy and to monitor the health of both mothers and their infants up to 10 weeks after…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on tough pancreatic cancer in major trial
Disease control Recruiting nowThis study tests a new daily pill, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific KRAS G12D gene mutation. Participants must have already tried at least one standard treatment. The goal is to see if the new drug helps peopl…
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control Recruiting nowThis trial tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery can shrink high-risk liver cancer (cholangiocarcinoma) and reduce the amount of tissue that needs to be removed. About 27 patients with resectable tumors will receive…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for tough lung cancer: ABBV-706 faces off against standard care
Disease control Recruiting nowThis study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for pancreatic cancer: experimental drug combo enters large trial
Disease control Recruiting nowThis large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug MRG007 enters early human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug offers hope for lymphoma patients who Can't get transplants
Disease control Recruiting nowThis phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug YL211 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…
Phase: PHASE1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo targets rare bladder cancer
Disease control Recruiting nowThis phase II trial tests two drugs, lurbinectedin and avelumab, in people with a rare and aggressive bladder cancer called small cell carcinoma. Participants who have already had a drug like avelumab will receive only lurbinectedin; others will get both. The study aims to see if…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo targets tough ovarian cancers
Disease control Recruiting nowThis early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare cancers: drug combo shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with rare cancers of the bladder, urinary tract, or testicles. The study aims to see if these drugs can shrink tumors or slow disease progression. About 68 adults will receiv…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New weekly shot could help chinese adults shed pounds and control diabetes
Disease control Recruiting nowThis phase 3 trial is testing a once-weekly injection called enicepatide in 300 Chinese adults who are obese or overweight, with or without type 2 diabetes. The drug works by mimicking two gut hormones to reduce appetite and improve blood sugar control. Participants will receive …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New inhaled insulin combo aims to simplify diabetes care for teens
Disease control Recruiting nowThis study tests a new approach for teens (ages 10-17) recently diagnosed with type 1 diabetes. They will use an inhaled insulin called Afrezza along with a long-acting injected insulin. The goal is to see if this combination helps keep blood sugar in a healthy range and is safe …
Phase: PHASE2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New STING agonist drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Mismatched donor stem cell transplant could widen treatment access for sickle cell disease
Disease control Recruiting nowThis study tests a stem cell transplant using cells from mismatched unrelated or partially matched family donors for people with severe sickle cell disease and other transfusion-dependent anemias. The approach removes certain immune cells (T-cells) from the donated stem cells to …
Phase: PHASE1, PHASE2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a vaccine help fight Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental vaccine called YMN-136 in people with advanced liver, pancreatic, or biliary tract cancer that has progressed after standard treatment. The main goal is to check the vaccine's safety and find the best dose, while also seeing if it…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
AI-Powered food app and smart glucose monitor could transform diabetes management
Disease control Recruiting nowThis study tests whether an AI app called SnapD, which recognizes Thai food and estimates nutrition, can help people with type 2 diabetes and overweight improve their blood sugar control. Some participants will also use a continuous glucose monitor (CGM) that tracks sugar levels …
Phase: NA • Sponsor: Ramathibodi Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
A glucose Monitor's second chance: can it tame type 1 diabetes in High-Risk teens?
Disease control Recruiting nowThis pilot study tests whether intermittent use of a continuous glucose monitor (CGM), along with regular medical visits, diabetes education, and psychological support, can improve blood sugar control in children and adolescents with high-risk type 1 diabetes in the Dominican Rep…
Sponsor: Life for a Child Program, Diabetes Australia • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called LBL-024 combined with the chemotherapy paclitaxel in people with ovarian cancer that has become resistant to platinum-based treatments. The trial involves 110 participants and aims to see if the combination can shrink tumors and delay disease pr…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug targets tough pancreatic cancer in early trial
Disease control Recruiting nowThis phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
Disease control Recruiting nowThis early-phase trial is testing whether combining two experimental drugs, JAB-21822 and JAB-3312, can safely shrink or control advanced solid tumors that carry a specific KRAS G12C mutation. The study includes people with cancers like non-small cell lung, colorectal, or pancrea…
Phase: PHASE1, PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a tiny glucagon shot before workout stop blood sugar crashes in type 1 diabetes?
Disease control Recruiting nowThis study tests whether a low dose of glucagon, given before exercise, can prevent blood sugar drops in adults with type 1 diabetes who use an automated insulin pump. Eighteen participants will exercise after a meal, comparing glucagon to a standard glucose drink. The goal is to…
Phase: PHASE4 • Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail shows promise for recurrent ovarian and endometrial cancers
Disease control Recruiting nowThis study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people with ovarian or endometrial cancer that has come back but still responds to platinum-based treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 5…
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
MRNA vaccine takes on liver cancer in tiny early trial
Disease control Recruiting nowThis early study tests a PD-1 mRNA vaccine in 9 adults with advanced liver cancer that has not responded to standard treatments. The vaccine is given as weekly shots for four weeks, then a fifth shot a month later. The main goal is to check safety, but researchers will also see i…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Radioactive drug takes on standard therapy in lung cancer trial
Disease control Recruiting nowThis phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 a…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New liposomal drug takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…
Phase: PHASE1, PHASE2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill may help adults with rare adrenal disorder cut back on steroids
Disease control Recruiting nowThis study tests a new drug, atumelnant, in 150 adults with classic congenital adrenal hyperplasia (CAH). The goal is to see if it can safely control hormone levels and allow patients to take lower doses of their usual steroid medications. Participants will receive either atumeln…
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Simple foot exercises may ease diabetic nerve pain and prevent foot problems
Disease control Recruiting nowThis study tests whether a 12-week program of supervised foot and ankle exercises can help people with diabetes who have nerve damage in their feet. The exercises are done in groups at primary care clinics. Researchers will measure changes in symptoms, foot movement, and quality …
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Pancreas cancer surgery showdown: total removal may boost survival
Disease control Recruiting nowThis study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New study tracks Octreotide's Real-World impact on acromegaly over two years
Disease control Recruiting nowThis study follows 200 people with acromegaly who are using octreotide subcutaneous depot, a medication that helps control hormone levels. Researchers will monitor safety and effectiveness for up to two years in everyday clinical practice, not a controlled lab setting. The goal i…
Sponsor: Camurus AB • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Spirulina's secret protein may shield the liver during surgery
Disease control Recruiting nowThis trial tests whether phycocyanin, a natural protein from spirulina, can reduce liver injury and support recovery in adults having part of their liver removed due to intrahepatic cholangiocarcinoma. About 30 participants will take either phycocyanin or a placebo daily for thre…
Phase: NA • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Which scope technique wins for tiny rectal tumors?
Disease control Recruiting nowThis trial compares two minimally invasive endoscopic procedures—underwater endoscopic mucosal resection (UEMR) and endoscopic submucosal dissection (ESD)—for removing small rectal neuroendocrine tumors (NETs) that are 10 mm or smaller. The goal is to see if UEMR is as effective …
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a pill outsmart Tumors' defenses?
Disease control Recruiting nowThis trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Gene therapy trial offers hope for babies with rare, deadly metabolic disease
Disease control Recruiting nowThis study tests a one-time gene therapy called ECUR-506 in baby boys under 9 months old with a severe form of OTC deficiency, a genetic disorder that prevents the body from breaking down ammonia. The goal is to see if the treatment is safe and can reduce dangerous ammonia levels…
Phase: PHASE3 • Sponsor: iECURE, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for tough lung cancer: SLICK trial combines targeted drug with chemo
Disease control Recruiting nowThis study tests whether adding a new drug called cirtuvivint to standard chemotherapy can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will receive the combination…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a diabetes drug protect blood vessels in type 1 diabetes?
Disease control Recruiting nowThis phase 2 trial tests whether dulaglutide, a drug used for type 2 diabetes, can improve small blood vessel function in adults with type 1 diabetes. The study involves 47 participants aged 18-40 with long-standing type 1 diabetes. Researchers measure blood flow and insulin sens…
Phase: PHASE2 • Sponsor: AdventHealth Translational Research Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to boost insulin sensitivity in type 2 diabetes
Disease control Recruiting nowThis study tests a single dose of a new drug, ALN-4324, to see if it improves how the body uses insulin in people with type 2 diabetes. About 40 adults who are on a stable dose of metformin will take part. The main goal is to measure changes in insulin sensitivity using a glucose…
Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a tailored diet before surgery boost liver cancer recovery?
Disease control Recruiting nowThis trial tests whether a personalized nutrition plan, combined with exercise and psychological support before surgery, can improve outcomes for people with primary liver cancer. Participants are randomly assigned to receive either standard dietary advice or an enhanced program …
Phase: NA • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for bile duct cancer: drug may delay return after surgery and chemo
Disease control Recruiting nowThis study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a diabetes drug curb alcohol cravings and save livers?
Disease control Recruiting nowThis study tests whether tirzepatide, a drug approved for weight management, can help people with alcohol use disorder and related liver disease drink less and improve liver health. 120 adults will receive weekly injections of tirzepatide or a placebo for 12 weeks. Researchers wi…
Phase: PHASE2 • Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a simple algorithm help doctors write better exercise prescriptions?
Disease control Recruiting nowThis study tests a new digital tool called P3-EX that helps doctors create personalized exercise plans for patients with heart disease risk factors like high blood pressure, diabetes, and obesity. Researchers will recruit 24 doctors and 48 patients to compare the new tool with a …
Phase: NA • Sponsor: University of Connecticut • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for tough lung cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a gut microbiome transplant boost fertility in PCOS?
Disease control Recruiting nowThis trial investigates whether taking capsules containing freeze-dried fecal matter from healthy donors—known as fecal microbiota transplantation (FMT)—can improve pregnancy outcomes and metabolic health in overweight or obese women with polycystic ovary syndrome (PCOS) who are …
Phase: NA • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: experimental drug ubamatamab enters phase 2 trials
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot could help tame stubborn Graves' disease
Disease control Recruiting nowThis study tests a drug called efgartigimod, given as a shot under the skin, for adults with Graves' disease whose thyroid levels are still too high despite taking standard antithyroid drugs. About 230 people will take part, and some will get the drug while others get a placebo. …
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug azenosertib takes on Chemo-Resistant ovarian cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…
Phase: PHASE3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without lifelong pills
Disease control Recruiting nowThis trial tests a new drug called IMVT-1402 for adults with Graves' disease, a condition where the thyroid is overactive. The study will include 210 participants who still have high thyroid levels despite taking standard medications. Participants will receive either one of two d…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could help kids with rare hormone disorder cut back on steroids
Disease control Recruiting nowThis study tests a daily oral medication called atumelnant in children aged 1 to 18 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone production. The goal is to see if the drug can safely normalize hormone levels and allow patients to lower th…
Phase: PHASE2, PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug KUP-101A enters first human tests for advanced skin cancers
Disease control Recruiting nowThis early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…
Phase: PHASE1 • Sponsor: Kupando GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase: PHASE1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could adding chest radiation extend life in advanced lung cancer?
Disease control Recruiting nowThis trial is testing whether adding radiation to the chest can help people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread widely. Participants first receive standard chemotherapy plus an immunotherapy drug, and if their cancer does not worsen,…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for hard-to-treat pancreatic cancer: drug combo aims to make tumors removable
Disease control Recruiting nowThis study tests a new drug (HRS-4642) combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in 30 people with locally advanced pancreatic cancer that has a specific gene change (KRAS G12D). The goal is to shrink tumors enough to allow surgery. Participants will ha…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Exercise and a diabetes drug: a One-Two punch for blood vessels?
Disease control Recruiting nowThis trial tests whether 16 weeks of exercise training, liraglutide treatment, or both can improve blood vessel function and insulin sensitivity in adults with type 2 diabetes. Participants are randomly assigned to one of three groups and are studied before and after the interven…
Phase: PHASE4 • Sponsor: University of Virginia • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can donor immune cells boost lung cancer remission?
Disease control Recruiting nowThis trial is for people with extensive-stage small cell lung cancer who have completed initial chemotherapy plus immunotherapy and have stable or improved disease. Participants are randomly assigned to receive either standard immunotherapy alone or immunotherapy combined with in…
Phase: PHASE2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare thymic cancer: targeted drug trial launches
Disease control Recruiting nowThis phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum-based chemotherapy. Participants receive the drug every two weeks, and doctors will check how well it shrinks tumors and monitor s…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Smart insulin system aims to protect moms and babies in diabetes pregnancy
Disease control Recruiting nowThis study tests whether an automated insulin delivery system (CamAPS FX) can help women with type 1 diabetes maintain better blood sugar control before and during pregnancy, compared to their usual insulin routine. The trial will enroll 305 women aged 18-45 who are either planni…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase: PHASE1, PHASE2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill reverse eye bulging in thyroid eye disease?
Disease control Recruiting nowThis clinical trial tests whether an oral medication called linsitinib can reduce eye bulging (proptosis) in people with moderate to severe active thyroid eye disease (TED). Participants will take either linsitinib or a placebo twice daily for 24 weeks. The main goal is to see if…
Phase: PHASE3 • Sponsor: Sling Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New enzyme pill could help cystic fibrosis patients digest food better
Disease control Recruiting nowThis study tests a new medicine called ANG003 for people with cystic fibrosis who have trouble digesting food (exocrine pancreatic insufficiency). The medicine is a type of enzyme replacement therapy, similar to the current standard treatment Creon. About 113 participants will re…
Phase: PHASE2 • Sponsor: Anagram Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New wearable could double diabetes monitoring power
Disease control Recruiting nowThis study is testing a new wearable device that continuously measures both glucose (sugar) and ketone levels in adults with type 1 diabetes. The device is worn for 15 days and its readings are compared to standard lab tests. The goal is to see if it is accurate and safe enough f…
Phase: NA • Sponsor: Henan University of Science and Technology • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
App aims to supercharge GLP-1 weight-loss drugs with personalized meal plans
Disease control Recruiting nowThis trial tests whether a mobile app called NutriSteppe can improve blood sugar control and weight loss in adults with type 2 diabetes or obesity who are already taking GLP-1 medications like semaglutide. Over 12 weeks, half the participants will use the app for personalized mea…
Phase: NA • Sponsor: Kazakh Academy of Nutrition • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New oral drug shows promise for rare sun allergy conditions
Disease control Recruiting nowThis study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain and skin reactions to sunlight. The purpose is to check the long-term safety of an oral medication called dersimelagon. About 301 participant…
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for liver cancer: Triple-Drug cocktail enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) works better than STRIDE alone for people with advanced liver cancer that cannot be surgically removed. About 140 adults who have not had prior systemic therapy will be enrolle…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Weekly shot could replace daily growth hormone for kids
Disease control Recruiting nowThis phase 3 trial compares a once-weekly growth hormone injection (lonapegsomatropin) to a daily one (somatropin) in 186 prepubertal children with growth failure due to Turner syndrome, SHOX deficiency, being small for gestational age, or idiopathic short stature. The goal is to…
Phase: PHASE3 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug aims to stop liver decline in PBC patients with cirrhosis
Disease control Recruiting nowThis Phase 3 trial tests whether seladelpar, a daily pill, can improve outcomes for people with primary biliary cholangitis (PBC) who also have compensated cirrhosis. About 318 adults will receive either seladelpar or a placebo for up to 36 months. The study tracks serious events…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without daily pills
Disease control Recruiting nowThis phase 2b trial tests an experimental drug called IMVT-1402 in 240 adults with Graves' disease whose thyroid is still overactive despite standard treatment. The goal is to see if the drug can help patients achieve normal thyroid hormone levels and stop taking antithyroid medi…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Weekly insulin shot could replace daily pokes for diabetes patients
Disease control Recruiting nowThis study tests if a new insulin that is injected just once a week works as well as daily insulin shots to control blood sugar in people with type 2 diabetes. About 586 adults who have never used insulin before will take either the weekly insulin or a standard daily insulin for …
Phase: PHASE4 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…
Phase: PHASE1, PHASE2 • Sponsor: Lumara Bio Oncologics GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted drug boost standard ovarian cancer therapy?
Disease control Recruiting nowThis trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo aims to control aggressive lung cancer
Disease control Recruiting nowThis early-phase study tests whether combining valemetostat with atezolizumab is safe as maintenance therapy for people with extensive-stage small cell lung cancer. Researchers will try different doses of valemetostat to find the best one with few side effects. The study involves…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New insulin pump system put to the test in 400-Person safety trial
Disease control Recruiting nowThis study is checking if a new insulin pump (NMX8) and continuous glucose monitor (DS5/Simplera Sync) are safe for people with type 1 or type 2 diabetes. About 400 participants, ages 7 to 85, will first wear the sensor for up to 40 days, then use the pump for about 90 days while…
Phase: NA • Sponsor: Medtronic MiniMed, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can adding a fourth drug shrink large liver tumors that invade the portal vein?
Disease control Recruiting nowThis trial is testing whether adding hepatic arterial infusion chemotherapy (HAIC) to a combination of lenvatinib, sintilimab, and drug-eluting bead chemoembolization (DEB-TACE) can better control large liver cancers (over 7 cm) that have spread into the portal vein. About 320 pa…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New chemo sequence aims to make pancreatic tumors operable
Disease control Recruiting nowThis phase 2 trial is testing whether giving two different chemotherapy regimens one after the other can shrink pancreatic tumors that are borderline or locally advanced, making them easier to remove surgically. The study enrolls 64 adults with pancreatic adenocarcinoma. Particip…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers by homing in on a specific protein
Disease control Recruiting nowThis study tests an experimental drug called SG1906 in people with advanced solid tumors that have a specific protein (CLDN18.2) on their surface. The trial has two parts: first, finding the safest dose, and then checking for early signs that the drug can shrink tumors. About 60 …
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Meals on wheels for diabetes: new study tests food delivery to fight hunger and improve health
Disease control Recruiting nowThis study tests whether a nutrition program that provides twice-daily meal delivery for up to 90 days after hospital discharge, plus diet education, can reduce food insecurity in people with type 1 or type 2 diabetes. About 160 hospitalized patients who screen positive for food …
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug aims to protect dialysis Patients' hearts
Disease control Recruiting nowThis study tests a drug called CSL300 in people with end-stage kidney disease who are on dialysis and have signs of inflammation. The goal is to see if it can reduce the risk of heart attacks or heart-related death. About 3110 adults will take part, and half will get the drug whi…
Phase: PHASE2, PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug MGC026 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Targeting the immune system: a new antibody may free Graves' patients from daily drugs
Disease control Recruiting nowThis phase 2 trial tests whether felzartamab, an antibody that targets immune cells producing harmful antibodies, can restore normal thyroid function in people with Graves' disease. Participants will receive either felzartamab or a placebo alongside their usual anti-thyroid drugs…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New weekly shot aims to stop liver disease from getting worse
Disease control Recruiting nowThis Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to protect kidneys in diabetes
Disease control Recruiting nowThis Phase 2 trial tests two experimental drugs, ALN-ANG3 and evinacumab, in 270 people with diabetic kidney disease. The drugs block a protein called ANGPTL3 to lower blood fats. Researchers will measure changes in urine protein and kidney function over time to see if the drugs …
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a diabetes drug help heal fatty livers?
Disease control Recruiting nowThis study looks at how the liver responds to food and a drug called semaglutide in people with non-alcoholic fatty liver disease (NAFLD). About 84 adults, including healthy volunteers, will take part. Researchers will check if semaglutide can reduce liver fat and damage over 30 …
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New weekly shot aims to tame type 2 diabetes
Disease control Recruiting nowThis study tests a new medicine called UBT251, given as a weekly shot, in 300 adults with type 2 diabetes. Some participants will get UBT251, others will get a placebo or an existing drug (semaglutide). The goal is to see if UBT251 can safely lower blood sugar and help with weigh…
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Diabetes drug tirzepatide tested for type 1 in new trial
Disease control Recruiting nowThis study tests whether tirzepatide, a drug used for type 2 diabetes, can help people with type 1 diabetes. Researchers will measure how the body responds to insulin and meals before and after 6 weeks of treatment. 44 adults with type 1 diabetes who use an automated insulin pump…
Phase: PHASE2 • Sponsor: Victor Chang Cardiac Research Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug BGB-B455 targets tough tumors in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy aims to freeze and burn liver cancer
Disease control Recruiting nowThis study tests a device that uses both freezing and heating to destroy liver tumors in people with liver cancer or colorectal cancer that has spread to the liver. The goal is to see if this approach improves how long patients live without their cancer growing, and whether it ac…
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
MRNA cancer shots: new hope or hype?
Disease control Recruiting nowThis early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a phone app tame gestational diabetes?
Disease control Recruiting nowThis trial tests whether a smartphone app called SPARK can help women with gestational diabetes manage their condition. Participants receive standard care, and some also use the app to support healthy eating, physical activity, and blood sugar tracking. The study looks at blood s…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …
Phase: PHASE1 • Sponsor: SHY Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New weekly shot could reverse liver damage in MASH patients
Disease control Recruiting nowThis phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug tackle Hard-to-Treat gynecologic cancers?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug may reduce insulin shots for young diabetes patients
Disease control Recruiting nowThis study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if teplizumab can help control blood sugar and reduce the need for insulin at mealtimes. Participants will receive either teplizumab or a placebo …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New weekly shot could transform diabetes care
Disease control Recruiting nowThis study tests a new once-weekly injection called NNC0662-0419 in 270 adults with type 2 diabetes. It compares the drug against a placebo and an approved medication, semaglutide, to see how well it controls blood sugar and promotes weight loss. The trial is currently recruiting…
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can tailored fluid dosing tame pancreatitis?
Disease control Recruiting nowThis trial tests whether giving fluids based on real-time changes in stroke volume—a measure of how much blood the heart pumps—can improve outcomes in people with moderate to severe acute pancreatitis. Standard care uses a fixed weight-based amount, which can sometimes lead to fl…
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Daily pill aims to tackle weight and diabetes together
Disease control Recruiting nowThis phase 3 study tests aleniglipron, an oral medication taken once daily, for helping adults with obesity or overweight and type 2 diabetes manage their weight over the long term. Participants receive either aleniglipron or a placebo for 76 weeks. The main goal is to see how mu…
Phase: PHASE3 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Personalized cell therapy aims to tame type 1 diabetes in early trial
Disease control Recruiting nowThis early-stage study is testing a new treatment called GNTI-122 for adults who were recently diagnosed with type 1 diabetes. The therapy is made from a person's own blood cells and is designed to help rebalance the immune system. Sixteen participants will receive either a low o…
Phase: PHASE1 • Sponsor: GentiBio, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can online therapy stop insulin resistance in HIV patients? new trial aims to find out
Disease control Recruiting nowThis study tests whether an internet-based depression treatment called cognitive behavioral therapy (iCBT-D) can prevent insulin resistance from getting worse in adults with HIV who are on antiretroviral therapy and have depression. Researchers will compare the online therapy pro…
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to boost IVF success for women with hormone deficiency
Disease control Recruiting nowThis Phase 3 trial tests a new combination of two hormones (follitropin alfa and lutropin alfa) against a standard treatment (hMG) for Japanese women with LH and FSH deficiency who are undergoing IVF. The goal is to see which treatment helps produce more eggs for retrieval. About…
Phase: PHASE3 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo targets genetic fatty liver in Mid-Stage trial
Disease control Recruiting nowThis Phase 2a trial is testing a new drug called ALN-PNP, alone or with a weight-loss drug (tirzepatide), in 204 adults with a specific genetic form of fatty liver disease (MASLD). The goal is to see if lowering a certain liver protein can reduce liver fat. Participants must have…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could adding radiation to immunotherapy keep lung cancer at bay?
Disease control Recruiting nowThis study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill takes on Hard-to-Treat KRAS cancers
Disease control Recruiting nowThis study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…
Phase: PHASE1, PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Electromagnetic fields join the fight against pancreatic cancer
Disease control Recruiting nowThis study tests whether adding a device that delivers amplitude-modulated radiofrequency electromagnetic fields (Therabionic P1) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control metastatic pancreatic cancer. About 30 adults with advanced pancreatic canc…
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Higher dose hormone therapy aims to control rare calcium disorder
Disease control Recruiting nowThis phase 3 trial tests higher daily doses (over 30 mcg) of palopegteriparatide (Yorvipath) in 36 adults with chronic hypoparathyroidism. Participants already on the drug will have their dose adjusted to find the best level for controlling calcium without needing extra vitamin D…
Phase: PHASE3 • Sponsor: Ascendis Pharma Bone Diseases A/S • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for teens with type 2 diabetes: Higher-Dose dulaglutide under study
Disease control Recruiting nowThis study tests two higher doses (3.0 mg and 4.5 mg) of the diabetes drug dulaglutide in teenagers aged 10 to 17 with type 2 diabetes. The goal is to see if these doses are safe and help control blood sugar and weight. Participants will receive weekly injections for about 8 mont…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New study: can a Two-Week monitor improve blood sugar control for new insulin users?
Disease control Recruiting nowThis study looks at whether wearing a continuous glucose monitor (CGM) for two weeks after leaving the hospital helps people with diabetes who are starting insulin for the first time. About 150 adults with type 1 or type 2 diabetes will be randomly assigned to use either a CGM or…
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill combo aims to shield hearts in diabetes patients
Disease control Recruiting nowThis large phase 3 trial is testing whether adding vicadrostat to the existing drug empagliflozin can reduce the risk of heart problems in adults with type 2 diabetes, high blood pressure, and heart disease. About 11,800 participants will take either the combination or a placebo …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Experimental drug DM005 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…
Phase: PHASE1, PHASE2 • Sponsor: Doma Biopharmaceutical(Suzhou)Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New diabetes pill icovamenib enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests whether a new drug called icovamenib can help people with type 2 diabetes who still have high blood sugar despite taking other medications. About 60 adults aged 18 to 70 will receive either icovamenib or a placebo daily for 12 weeks. The main goal is to s…
Phase: PHASE2 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Phase: PHASE1, PHASE2 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug shows promise in reversing liver scarring in major trial
Disease control Recruiting nowThis Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for low blood counts after CAR T-Cell therapy?
Disease control Recruiting nowThis study tests a drug called emapalumab to see if it can safely help people whose blood cell counts stay dangerously low after CAR T-cell therapy for certain lymphomas. About 32 adults who have already received standard CAR T-cell therapy will take part. The goal is to find out…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Shorter maintenance therapy may be just as effective for BRCA-Linked ovarian cancer
Disease control Recruiting nowThis phase 3 trial tests whether taking the drug olaparib for one year works as well as taking it for two years to keep ovarian cancer from coming back. The study includes 880 people with advanced ovarian cancer (stage III or IV) who have a BRCA mutation or similar DNA repair pro…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for kids with tough cancers: GAIA-102 trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…
Phase: PHASE1 • Sponsor: Kyushu University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Experimental cocktail aims to outsmart tough lung cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two experimental drugs, tarlatamab and ZL-1310, with or without the immunotherapy durvalumab, can safely shrink tumors in people with small cell lung cancer that has worsened after standard treatment. About 160 adults will take …
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can stomach cancer surgery also tame diabetes?
Disease control Recruiting nowThis trial tests three different ways to reconnect the digestive tract after stomach cancer surgery to see which one best controls blood sugar in people who also have type 2 diabetes. Participants will be randomly assigned to one of three surgical procedures. The main goal is to …
Phase: NA • Sponsor: Korea University Anam Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat GI cancers
Disease control Recruiting nowThis study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid in Graves' disease
Disease control Recruiting nowThis study tests whether BHV-1300 can help adults with Graves' disease achieve normal thyroid function without antithyroid drugs. Participants receive either BHV-1300 or a placebo via injection. The main goal is to see if more people on BHV-1300 have normal thyroid hormone levels…
Phase: PHASE3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can community hospitals in zambia master severe disease care?
Disease control Recruiting nowThis trial tests a new model of care called PEN-Plus, which brings specialized treatment for severe chronic diseases like diabetes, heart conditions, and sickle cell disease to first-level hospitals in Zambia. The goal is to train local health workers and set up clinics to manage…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug cocktail takes on rare adrenal cancer
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy cemiplimab to the targeted drug cabozantinib works better than cabozantinib alone for advanced adrenocortical cancer. About 48 adolescents and adults whose cancer has spread or cannot be removed will take part. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New immune therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Exercise as medicine: tailored workouts may rebuild strength after cancer
Disease control Recruiting nowThis trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…
Phase: NA • Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for neuroendocrine tumors: zanzalintinib takes on everolimus
Disease control Recruiting nowThis study compares a new drug, zanzalintinib, to the current standard drug everolimus in people with advanced neuroendocrine tumors that have already been treated. The goal is to see which drug better slows tumor growth. About 440 participants will be randomly assigned to one of…
Phase: PHASE2, PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for tough lung cancer: expanded access to targeted drug
Disease control AVAILABLEThis program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…
Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug aims to control type 1 diabetes early
Disease control Recruiting nowThis study tests a new drug, CNP-103, in people aged 12 to 35 who were diagnosed with stage 3 type 1 diabetes within the last 6 months. The goal is to see if the drug is safe and can help control the disease. Participants will receive either the drug or a placebo, and researchers…
Phase: PHASE1, PHASE2 • Sponsor: COUR Pharmaceutical Development Company, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Sleep your way to better blood sugar? new study tests behavioral fix for type 1 diabetes
Disease control Recruiting nowThis study tests whether a 12-week sleep-focused behavioral program can help adults with type 1 diabetes improve their sleep and blood sugar control. Participants learn sleep hygiene, stress management, and routines to target 7-9 hours of quality sleep. The study tracks sleep wit…
Phase: NA • Sponsor: Emory University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New Antibody-Like drug could boost chemo for rare cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental drug combo aims to extend cancer control in lung cancer
Disease control Recruiting nowThis trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug STRO-004 takes on advanced cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can these diabetes drugs stop liver failure? major trial launches
Disease control Recruiting nowThis large phase 3 study is testing whether two drugs, tirzepatide and retatrutide, can prevent major liver complications in 4,500 adults with high-risk metabolic fatty liver disease (MASLD). Participants are randomly assigned to receive one of the drugs or a placebo for about 4 …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Hope for Platinum-Resistant ovarian cancer: new pill takes on chemo
Disease control Recruiting nowThis Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug PHN-012 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Online shopping tricks aim to boost whole grain intake in diabetes patients
Disease control Recruiting nowThis study tests whether personalized marketing messages and discounts can encourage people with prediabetes or type 2 diabetes to switch from refined grains to whole grains when shopping for groceries online. About 216 adults aged 45-70 from the Philadelphia area who already sho…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for ovarian cancer: phase 3 trial tests targeted drug against Tough-to-Treat tumors
Disease control Recruiting nowThis large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo targets fatty liver in major trial
Disease control Recruiting nowThis study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…
Phase: PHASE2 • Sponsor: Eccogene • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug hopes to tackle MASH cirrhosis
Disease control Recruiting nowThis study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New vaccine aims to halt ovarian cancer recurrence detected in blood
Disease control Recruiting nowThis phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could Once-Daily radiation replace Twice-Daily for breast cancer recurrence?
Disease control Recruiting nowThis study is for women whose breast cancer has come back after initial breast-conserving surgery and whole breast radiation. The standard treatment after repeat surgery is radiation twice a day for 30 sessions. This trial tests whether giving radiation once a day for 15 sessions…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a daily pill replace growth hormone shots for kids?
Disease control Recruiting nowThis study tests an oral medication called LUM-201 for children with growth hormone deficiency who have never been treated before. The goal is to see if taking a pill every day for 12 months can improve growth rate compared to a placebo. The study involves 150 prepubertal childre…
Phase: PHASE3 • Sponsor: Lumos Pharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Old drugs, new hope: could a thalidomide combo free thalassemia patients from transfusions?
Disease control Recruiting nowThis study tests whether a combination of two drugs, thalidomide and hydroxyurea, can safely boost fetal hemoglobin levels in people with beta thalassemia major. The goal is to improve overall hemoglobin levels and reduce the need for regular blood transfusions. The trial include…
Phase: NA • Sponsor: Riphah International University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New study pits two drug combos against stubborn thyroid cancer
Disease control Recruiting nowThis phase III trial is for people with a specific type of thyroid cancer (BRAF V600E-mutated) that doesn't respond to radioactive iodine. It compares two treatment options: a combination of dabrafenib and trametinib versus cabozantinib alone. The goal is to see which is safer an…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Implantable pump could ease diabetes management for 40 patients
Disease control Recruiting nowThis study is testing a new implantable insulin pump (MIIPS 2020) in 40 adults with type 1 diabetes whose blood sugar is hard to control with standard insulin shots or external pumps. The pump is placed inside the body and delivers insulin directly, aiming to reduce dangerous hig…
Phase: NA • Sponsor: Medtronic MiniMed, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for hard-to-treat ovarian cancer: experimental drug targets key protein
Disease control Recruiting nowThis study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New diabetes drug aims to help when current meds fall short
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called LY3457263 in 240 adults with type 2 diabetes who still have high blood sugar despite taking stable doses of semaglutide or tirzepatide. Participants receive weekly injections of either the new drug or a placebo for about 9 mont…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New shot aims to tame hepatitis b without daily pills
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop the…
Phase: PHASE2 • Sponsor: AusperBio Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New weekly shot could help people with obesity and diabetes shed pounds
Disease control Recruiting nowThis study tests a new once-weekly medicine called eloralintide to help people with obesity or overweight and type 2 diabetes lose weight. About 1035 adults will receive either the drug or a placebo for around 75 weeks. Researchers will measure changes in body weight, fat, waist …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Nanomechanical biopsy could revolutionize pancreatic cancer care
Diagnosis Recruiting nowThis study tests a new technology called NEO-Match® that measures the stiffness of pancreatic tissue from a biopsy sample. Researchers want to see if this test can predict how well a patient will respond to cancer treatment and help diagnose pancreatic cancer more accurately. Abo…
Phase: NA • Sponsor: ARTIDIS AG • Aim: Diagnosis
Last updated Aug 19, 2026 10:00 UTC
-
Blood test may spot active testicular cancer, study seeks proof
Diagnosis Recruiting nowThis study is testing whether a blood test that measures a substance called miRNA-371 can accurately detect active testicular cancer in people who have already had their primary tumor removed. Researchers will compare the blood test results with surgical findings to see how well …
Sponsor: University of Southern California • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New ultrasound technique could replace needle test for liver pressure
Diagnosis Recruiting nowThis study tests whether a special ultrasound technique (SHAPE) can detect high blood pressure in the liver without using a needle. Portal hypertension is a serious condition that can lead to severe liver damage and death. The standard test requires inserting a catheter into a ve…
Phase: NA • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Could a Stick-On sensor replace the glucose drink test for pregnancy diabetes?
Diagnosis Recruiting nowThis pilot study will enroll 150 pregnant individuals to see if a continuous glucose monitor (CGM) can accurately diagnose gestational diabetes. Participants will wear a small sensor on their arm that measures blood sugar continuously. The results will be compared to the standard…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Blood test may predict kidney decline in diabetes — a large trial investigates
Diagnosis Recruiting nowThis study is testing whether a diagnostic test called KidneyIntelX can help primary care doctors improve care for people with type 2 diabetes and chronic kidney disease. The test predicts the risk of kidney function worsening. Researchers will see if using this test leads to mor…
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Can AI spot ovarian cancer on CT scans before It's too late?
Diagnosis Recruiting nowThis study is testing whether an artificial intelligence (AI) tool called CAT-OV can accurately identify ovarian cancer on CT scans. Ovarian cancer is often found late, when it's harder to treat, and current screening methods aren't reliable enough. The AI is being trained and te…
Sponsor: Chang Gung Memorial Hospital • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Blood test could outshine ultrasound in liver cancer screening
Diagnosis Recruiting nowThis phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new PET tracer light up hidden cancers?
Diagnosis Recruiting nowThis trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…
Phase: NA • Sponsor: Peking University Third Hospital • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
A new imaging agent could tell doctors which liver cancers will resist immunotherapy
Diagnosis Recruiting nowThis trial is testing whether a special PET/CT scan using 18F-fluorocholine, along with a liquid biopsy, can predict how well patients with inoperable liver cancer (hepatocellular carcinoma) will respond to immunotherapy. The study enrolls adults with this type of liver cancer wh…
Phase: PHASE2 • Sponsor: Queen's Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New PET scan tracer could light up hidden lung cancers
Diagnosis Recruiting nowThis study tests a new radioactive tracer called 89Zr-DFO-SC16.56 that attaches to a protein called DLL3 found on small cell lung cancer cells. The goal is to see if PET scans using this tracer can safely and accurately show where the cancer is in the body. About 53 adults with s…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New ultrasound could replace painful liver biopsies
Diagnosis Recruiting nowThis study is testing a new ultrasound technique called visual transient elastography (ViTE) to measure liver fat and scarring in people with chronic liver injury. Researchers will compare the ultrasound results to the standard liver biopsy to see how accurate the new method is. …
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
A new test could reveal how radiation affects the liver
Diagnosis Recruiting nowThis pilot study explores whether a combination of advanced MRI scans and a blood test called HepQuant DuO can measure liver function in people receiving radiation therapy for liver cancer. The study will enroll about 40 adults with liver cancer or liver metastases. The goal is t…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
Wearable sensor may replace the dreaded glucose drink test for gestational diabetes
Diagnosis Recruiting nowThis study tests whether a continuous glucose monitor (CGM) worn on the arm can diagnose gestational diabetes as well as the standard oral glucose tolerance test (OGTT). Pregnant women of Chinese or Indian ethnicity will wear the sensor for up to 10 days and also undergo the OGTT…
Phase: NA • Sponsor: KK Women's and Children's Hospital • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a simple blood test catch Cushing's earlier?
Diagnosis Recruiting nowThis study aims to improve how doctors diagnose Cushing's syndrome, a condition caused by too much cortisol. Researchers will test the accuracy of the desmopressin stimulation test in 140 people aged 18-70 who have or may have Cushing's, plus healthy volunteers. Participants will…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can AI catch the leading cause of blindness before It's too late?
Diagnosis Recruiting nowThis trial is testing whether an artificial intelligence (AI) model, called MONA DR, can accurately detect diabetic retinopathy—a common eye complication of diabetes that can lead to blindness—from retinal photographs. The study will enroll 100 adults with diabetes and compare th…
Sponsor: West German Center of Diabetes and Health • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New scan could spot pancreatic cancer more clearly
Diagnosis Recruiting nowThis study tests a special PET scan that uses a radioactive tracer called 68Ga-FAPI-46 to highlight pancreatic cancer cells. The goal is to see if this scan can find tumors more accurately than current methods. About 130 adults with early-stage pancreatic cancer will get the scan…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
A Finger-Prick could change the fight against hepatitis c
Diagnosis Recruiting nowThis large Australian study is testing whether offering a finger-stick point-of-care test for hepatitis C can increase diagnosis and treatment rates. Adults at risk for hepatitis C will be offered the rapid test at services they already use. Those who test positive for the virus …
Sponsor: Kirby Institute • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
Can a radioactive tracer light up hidden tumors? a new trial aims to find out
Diagnosis Recruiting nowThis Phase I trial is testing an experimental imaging drug, 203Pb-RMX-VH-PIB, to see how it spreads through the body and how much radiation reaches different organs. The study includes adults with glioblastoma (a type of brain cancer) or pancreatic cancer. Participants receive a …
Phase: PHASE1 • Sponsor: Radiomedix, Inc. • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
A simple finger prick could transform hepatitis c care
Diagnosis Recruiting nowThis large Australian study is testing whether offering finger-stick point-of-care testing for hepatitis C in community settings—like drug treatment clinics, homeless shelters, and prisons—can increase the number of people diagnosed and linked to treatment. The study will include…
Sponsor: Kirby Institute • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
Can a new PET tracer spot thyroid cancer recurrence more clearly?
Diagnosis Recruiting nowThis trial is evaluating whether a new PET/CT imaging tracer, 68Ga-MY6349, can detect recurrent or metastatic thyroid cancer more effectively than the standard 68Ga-FAPI tracer. Adults with a history of treated thyroid cancer who show signs of possible recurrence will receive bot…
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
Hormone boost may shield soldiers from training injuries
Prevention Recruiting nowThis trial tests whether altering sex hormone levels can make muscles, tendons, and bones more resilient to the physical and mental stress of military-style training. Healthy adults aged 18-40 will undergo a 4-week training program, with some receiving goserelin to suppress hormo…
Phase: PHASE4 • Sponsor: Bradley Nindl • Aim: Prevention
Last updated Aug 19, 2026 10:00 UTC
-
Vitamin d dosing trial aims to stop prediabetes from becoming diabetes
Prevention Recruiting nowThis study tests whether taking weekly vitamin D supplements, with doses adjusted to reach a target blood level, can help control blood sugar in 100 adults aged 30-74 who have prediabetes (high risk for type 2 diabetes). Participants are randomly assigned to receive vitamin D or …
Phase: PHASE3 • Sponsor: Tufts Medical Center • Aim: Prevention
Last updated Aug 19, 2026 10:00 UTC
-
Could a smaller dose of nutrients protect kids from malnutrition?
Prevention Recruiting nowThis study compares two types of nutrient supplements—small-quantity and medium-quantity—to see if the smaller one works just as well at preventing undernutrition in children aged 6 to 12 months. About 980 infants in Pakistan will receive one of the two supplements daily for 6 mo…
Phase: NA • Sponsor: Aga Khan University • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New program aims to boost cervical cancer screening in high-risk women
Prevention Recruiting nowThis study tests a program called PINPOINT that helps women with obesity or diabetes get screened for cervical cancer. About 20 women who are behind on screening will be offered options like self-collection or a Pap smear. The goal is to see if the program is practical and well-l…
Phase: NA • Sponsor: University of Florida • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
Could a less drastic surgery prevent ovarian cancer in High-Risk women?
Prevention Recruiting nowThis study looks at two surgeries to reduce ovarian cancer risk in women with BRCA1 gene changes. One surgery removes only the fallopian tubes, while the other removes both tubes and ovaries. Researchers want to see if removing just the tubes works nearly as well at preventing ca…
Phase: NA • Sponsor: NRG Oncology • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Can coaching clinics curb HIV? a new strategy puts it to the test
Prevention Recruiting nowThis study tests whether a 'practice coaching' program can help opioid treatment clinics offer more HIV and hepatitis C testing to their patients. Clinics are randomly assigned to receive either coaching focused on HIV testing, coaching that adds hepatitis C testing, or just info…
Phase: NA • Sponsor: Columbia University • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Could a pill delay diabetes in kids? new trial hopes so
Prevention Recruiting nowThis study tests whether the drug baricitinib can delay the onset of type 1 diabetes in children aged 1 to 36 months who are at high risk. Participants take baricitinib or a placebo daily for up to 5 years. The goal is to see if the drug can push back or prevent the need for insu…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Diet and exercise combo tested to stop prediabetes becoming diabetes
Prevention Recruiting nowThis study looks at whether adding supervised cycling and rowing to a Mediterranean diet improves blood sugar control better than diet alone in women with prediabetes. Thirty women will be split into three groups based on their current blood sugar levels. They will follow the die…
Phase: NA • Sponsor: Begüm Yücesoy Güneysu • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Can music tame blood sugar and anxiety before surgery?
Symptom relief Recruiting nowThis trial tests whether listening to meditation music before and after elective surgery can help adults with type 2 diabetes control their blood sugar, feel less anxious, and sleep better. Participants are randomly assigned to receive either routine care plus self-selected medit…
Phase: NA • Sponsor: İstanbul Aydın Üniversitesi • Aim: Symptom relief
Last updated Aug 19, 2026 10:00 UTC
-
Simple oral care by diabetes doctors may ease dry mouth
Symptom relief Recruiting nowDiabetes patients often suffer from dry mouth, which affects eating, speaking, and quality of life. This study tests whether endocrinologists can deliver simple oral care—like screening, counseling, and saliva substitutes—during routine diabetes visits. Researchers will follow 80…
Phase: NA • Sponsor: Khyber Medical University Peshawar • Aim: Symptom relief
Last updated Aug 19, 2026 10:00 UTC
-
Cancer injection satisfaction study recruits 700 patients
Symptom relief Recruiting nowThis study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …
Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
New hope for men battling hot flashes from prostate cancer treatment
Symptom relief Recruiting nowThis study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…
Phase: PHASE2 • Sponsor: Shehzad Basaria, M.D. • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
New CGM training program aims to help seniors with diabetes
Symptom relief Recruiting nowThis study tests a three-session training program to help older adults (65+) who use insulin learn to use a continuous glucose monitor (CGM). Participants will be randomly assigned to the program or standard training. The goal is to see if the program improves how often they wear…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Gamified learning boosts diabetes know-how in kids, trial hopes
Symptom relief Recruiting nowThis study tests whether a gamified education program can improve health literacy and quality of life in children aged 8-12 with type 1 diabetes. Half of the 52 participants will receive the gamified program plus standard education, while the other half gets standard education al…
Phase: NA • Sponsor: KTO Karatay University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Could a daily powder ease PCOS symptoms? a trial puts it to the test.
Symptom relief Recruiting nowThis trial tests whether a dietary supplement called MILAMEND Hormone Balance can improve quality of life and hormonal health in women aged 18-40 who have PCOS or likely have it. Participants take the supplement or a placebo daily for several months, tracking their menstrual cycl…
Phase: NA • Sponsor: Mila Mend Inc. • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Breakfast order may tame blood sugar spikes in pregnancy diabetes
Symptom relief Recruiting nowThis study tests whether eating protein and fat (scrambled eggs) before carbohydrates (toast) can reduce blood sugar spikes in women with gestational diabetes. Thirty-five pregnant women will eat the same breakfast in two different orders on separate days, acting as their own con…
Phase: NA • Sponsor: Queen's University, Belfast • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New program aims to ease burden on caregivers of cancer and diabetes patients
Symptom relief Recruiting nowThis study tests a program called enCompass Humana, which provides coaching and resources to unpaid caregivers of adults with both cancer and diabetes. The goal is to see if the program is practical and helpful for caregivers, improving their coping skills and reducing loneliness…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Smart bandage zaps chronic wounds to speed healing
Symptom relief Recruiting nowThis pilot study tests a new flexible bandage called exciflex that delivers mild electrical stimulation to chronic wounds that won't heal normally. The study includes 16 veterans with diabetes or spinal cord injury who have lower leg wounds. The bandage is designed to work for up…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Digital therapy aims to tame the fear that haunts cancer survivors
Symptom relief Recruiting nowThis trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Guarana: a natural energy boost for cancer fatigue?
Symptom relief Recruiting nowThis phase 2 trial tests whether guarana, a natural supplement from the Amazon, can reduce fatigue in 86 people with neuroendocrine tumors or gynecologic cancers. Participants take either guarana or a placebo daily for up to 42 days, and researchers measure changes in fatigue usi…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Could fasting boost chemo outcomes? small trial tests the idea in ovarian cancer
Symptom relief Recruiting nowThis study looks at whether intermittent fasting (not eating for 16 hours a day, 5 days a week) is safe and doable for people with advanced ovarian cancer who are getting chemotherapy before surgery. Twenty participants will either follow the fasting schedule or standard diet adv…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
Symptom relief Recruiting nowThis pilot study tests a care model called Patient Priorities Care (PPC) for older African Americans with heart disease plus other chronic conditions like diabetes or COPD. The approach shifts focus from treating each disease separately to aligning care with what matters most to …
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Can Real-Time feedback rewire walking in diabetic nerve damage?
Knowledge-focused Recruiting nowThis study compares walking patterns between people with diabetic peripheral neuropathy (nerve damage from diabetes) and healthy adults. It also tests whether giving people real-time feedback on their walking form can immediately change how they walk. The goal is to understand th…
Phase: NA • Sponsor: Florida Institute for Human and Machine Cognition • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
New imaging study aims to personalize thyroid cancer radiation doses
Knowledge-focused Recruiting nowThis study tests two ways of preparing people with advanced thyroid cancer for a special PET scan that uses a radioactive form of iodine (I-124). The goal is to see which preparation method gives better information for calculating the right dose of radiation therapy. Thirty parti…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Scientists hunt for genetic clues in lung and esophageal cancers
Knowledge-focused Recruiting nowThis study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Could a fatty liver fuel Alzheimer's? new scan aims to find out
Knowledge-focused Recruiting nowThis early-phase study tests a new way to use PET scans to measure inflammation in both the liver and brain at the same time. Researchers will scan 12 adults with fatty liver disease using two different tracers (18F-FDG and 18F-DPA-714) to see if the new method can reliably detec…
Phase: EARLY_PHASE1 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Scientists launch major study to uncover secrets of insulin resistance
Knowledge-focused Recruiting nowThis study aims to learn more about insulin resistance and diabetes by collecting blood and skin samples from up to 1,200 participants, including patients with severe insulin resistance and their family members. Researchers will study genetics and how insulin works in the body to…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
Knowledge-focused Recruiting nowThis study tests whether adding a technique called vascular deformation mapping (VDM) to standard CT scans can better predict liver failure after major liver surgery. Researchers will analyze routine preoperative CT images from over 1,000 adults undergoing removal of at least thr…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Can wearable sensors unlock better blood sugar control after kidney transplants?
Knowledge-focused Recruiting nowThis study uses continuous glucose monitors (CGMs) to track blood sugar levels in the days right after a kidney transplant. It compares three groups of recipients: those with diabetes, those with pre-diabetes, and those without diabetes. The goal is to see if glucose patterns dif…
Sponsor: Bo Feldt-Rasmussen • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
New study creates ovarian tissue databank to unlock fertility secrets
Knowledge-focused Recruiting nowThis study collects and stores ovarian tissue from females aged 4 to 35 who choose to freeze a sample before cancer treatment that could harm their fertility. Researchers will also gather medical data and annual surveys for up to 30 years. The goal is to build a national database…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Family study aims to unlock secrets of rare gut cancer
Knowledge-focused Recruiting nowThis study looks at families where multiple members have had small bowel carcinoid tumors, a rare and slow-growing cancer. Researchers want to learn how the disease develops, improve early detection, and find the genes that may cause it. Participants, including those with and wit…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Scientists hunt for better ways to spot hidden adrenal tumors
Knowledge-focused Recruiting nowThis study aims to improve how doctors find and understand pheochromocytomas and paragangliomas, rare tumors that can cause dangerous high blood pressure. Researchers will use advanced imaging scans and genetic testing in up to 3,000 participants to learn more about these tumors.…
Phase: PHASE1 • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Mining mountains of data to outsmart diabetes complications
Knowledge-focused Recruiting nowThis study is collecting blood, stool, genetic information, and health records from 1,200 Medicaid patients in South Carolina — some with type 2 diabetes and some without. Researchers will analyze this data to find patterns that could predict chronic kidney disease, a common comp…
Sponsor: Guardian Research Network, Inc. • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
10-Year study aims to predict dangerous calcium drop after thyroid removal
Knowledge-focused Recruiting nowThis study reviews 10 years of medical records from 600 adults who had thyroid surgery at Minia University Hospital. The goal is to find out which patients are most likely to develop low calcium levels after surgery, a common complication. By identifying key risk factors, doctors…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Cancer genetics study aims to personalize treatment
Knowledge-focused Recruiting nowThis study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Liver biopsies reveal Fat-Busting secrets in alcohol detox
Knowledge-focused Recruiting nowThis study looks at how the liver processes fat in people with alcohol use disorder who are quitting drinking. Researchers will take two small liver samples—one early in detox and one after four weeks—to compare gene activity. The goal is to understand how the liver clears fat wh…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Scientists launch deep dive into rare liver disease PSC
Knowledge-focused Recruiting nowThis study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatmen…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
Scientists launch 25-Year quest to unravel mystery fungal infections
Knowledge-focused Recruiting nowThis study aims to understand why some people get severe or unusual fungal infections due to immune system problems. Researchers will collect blood, tissue, and other samples from up to 1,200 participants over 25 years. No new treatments are being tested; the goal is to learn mor…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 19, 2026 10:00 UTC
-
AI may foresee lung complications after liver surgery
Knowledge-focused Recruiting nowThis study aims to build a digital early-warning system that uses machine learning to predict acute lung injury (ALI) in patients undergoing major liver surgery. By analyzing cardiopulmonary interaction characteristics, the model could help doctors identify at-risk patients early…
Sponsor: Beijing Tsinghua Chang Gung Hospital • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Could a recovery checklist speed healing after brain tumor surgery?
Knowledge-focused Recruiting nowThis study looks at whether a structured recovery program called Enhanced Recovery After Surgery (ERAS) can improve outcomes for people undergoing endoscopic surgery to remove pituitary tumors. Researchers will track complications, pain, nausea, hospital stay length, and readmiss…
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
New study investigates why heart disease hits african americans differently
Knowledge-focused Recruiting nowThis study looks at how obesity and body fat affect heart disease risk in 2,000 healthy African American men and women. Researchers will measure body fat, blood fats, and insulin function to see if risk factors differ by sex. The goal is to understand why heart disease rates are …
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Massive liver study seeks 8,000 volunteers to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Scientists seek clues to fungal infections in immune system study
Knowledge-focused Recruiting nowThis study aims to understand why some people are more prone to fungal infections, especially from Candida yeast. Researchers will collect blood, saliva, urine, and tissue samples from people with immune disorders, their family members, and healthy volunteers. No treatment is giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Fat cell 'Messages' may harm blood vessels — can exercise or surgery stop them?
Knowledge-focused Recruiting nowThis study looks at whether tiny particles released by fat cells, called adiposomes, carry harmful fats that damage blood vessels in people with obesity and type 2 diabetes. Researchers will test if a 12-week aerobic exercise program or weight-loss surgery can reduce these harmfu…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Scientists track Cancer's inner workings during radiation treatment
Knowledge-focused Recruiting nowThis study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can a simple monitor predict type 1 diabetes before symptoms start?
Knowledge-focused Recruiting nowThis study is testing whether a continuous glucose monitor (CGM) can predict blood sugar problems in people who are at risk for type 1 diabetes but have no symptoms. Researchers will follow 75 people aged 5 to 39 who have diabetes-related autoantibodies. They will compare CGM dat…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
NIH launches major study to unlock secrets of rare bone diseases
Knowledge-focused Recruiting nowThis study aims to collect information and bone samples from up to 1,000 people with bone or mineral disorders, such as tumor-induced osteomalacia or familial tumoral calcinosis. Participants receive standard medical evaluations and may provide bone tissue from surgery or a biops…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Scientists seek samples to unlock blood disorder secrets
Knowledge-focused Recruiting nowThis study collects biological samples like blood, saliva, and urine from 300 adults aged 18-70, both with and without blood disorders such as sickle cell disease and thalassemia. The goal is to use these samples for research to better understand these conditions and related dise…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Scientists bank tumors and blood to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can a simple audio diary app transform diabetes Self-Care?
Knowledge-focused Recruiting nowThis study is testing whether a mobile app called Fabla-diabetesMM, which lets people record audio diaries, is easy and helpful for older adults with type 1 or 2 diabetes who also have other health conditions. Thirty participants will use the app and answer questions about their …
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
Knowledge-focused Recruiting nowThis study investigates whether measuring whole-body metabolism—how the body uses energy—can reflect the metabolic changes in ovarian tumors and predict how well patients respond to chemotherapy. Researchers will measure resting metabolic rate and other metabolic markers in women…
Sponsor: University of Tennessee Graduate School of Medicine • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Massive study seeks to unlock how your surroundings and DNA shape disease risk
Knowledge-focused Recruiting nowThis study looks at how your genes and your environment—like what you eat, breathe, and experience—work together to influence common diseases such as diabetes, heart disease, and asthma. Researchers are collecting health questionnaires, genetic data, and other information from 25…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can a simple screening catch diabetes and heart disease before it starts?
Knowledge-focused Recruiting nowThis study will test a new screening program for 3,000 people turning 50 in the Ascoli Piceno province of Italy. Participants will fill out questionnaires and get a blood test to check their risk of developing type 2 diabetes and cardiovascular disease. The goal is to see if this…
Sponsor: Marche Region Regional Health Agency • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can we spot cancer before it starts? a massive study aims to find out
Knowledge-focused Recruiting nowThis study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Scientists investigate rare overgrowth disorder proteus syndrome
Knowledge-focused Recruiting nowThis study aims to understand the genetic and biological causes of Proteus syndrome, a rare condition causing abnormal growth of bones, skin, and other tissues. Researchers will follow up to 1,500 participants over time, using medical exams, imaging, and blood tests to track how …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
NIH launches major study to unravel hormone mysteries
Knowledge-focused Recruiting nowThis study at the National Institutes of Health is looking at 1,000 adults with known or suspected hormone gland (endocrine) disorders. The goal is to better understand these conditions and help train doctors. Participants may receive tests, treatments, or surgery as part of thei…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
NIH launches major study to uncover hidden causes of dangerous low blood sugar
Knowledge-focused Recruiting nowThis study aims to better understand why some people experience dangerously low blood sugar (hypoglycemia), especially after fasting. Researchers will admit 1,500 adults to the NIH Clinical Center for controlled fasting and a series of blood tests to measure insulin and other fac…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Scientists dive deep into endocrine tumors to unlock molecular secrets
Knowledge-focused Recruiting nowThis study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Millions of unpaid caregivers: study tracks hidden health toll
Knowledge-focused Recruiting nowThis study follows 2,800 unpaid caregivers of people with chronic conditions like diabetes or inherited disorders. Researchers will survey and interview caregivers over up to 5 years to track changes in their health, stress, and social support. The goal is to understand how careg…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
New study tracks safety of growth hormone drug in kids
Knowledge-focused Recruiting nowThis study is watching for side effects in 50 children in India who are prescribed somatrogon, a long-acting growth hormone injection for growth hormone deficiency. The goal is to see how safe the drug is during routine care over 3 years. Participants do not have to visit the cli…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can freezing ovarian tissue help people with turner syndrome or early menopause have kids?
Knowledge-focused Recruiting nowThis study looks at whether freezing ovarian tissue can help preserve fertility in people aged 2-21 with conditions like Turner syndrome, galactosemia, or premature ovarian insufficiency. Participants may have surgery to remove and freeze a gonad, with a small piece used for rese…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New blood test could spot pancreatic cancer sooner
Knowledge-focused Recruiting nowThis study aims to create a simple, minimally invasive test to find pancreatic cancer at an early stage and track how well treatment is working. Researchers will study 700 people with pancreatic cancer, pancreatitis, or pancreatic cysts. The goal is to identify biological markers…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Liver clues: a new way to stage heart amyloidosis?
Knowledge-focused Recruiting nowThis study looks at whether liver function and blood clotting tests can help doctors better understand and monitor cardiac transthyretin amyloidosis (ATTR-CA), a condition where abnormal protein builds up in the heart. Researchers will compare these tests in people with ATTR-CA a…
Sponsor: University of Messina • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Brain waves under the spotlight: a new clue to cyclic vomiting?
Knowledge-focused Recruiting nowThis study uses a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) to compare brain activity in people with cyclic vomiting syndrome (CVS) and healthy volunteers. The goal is to see if there are differences in cortical excitability—how easil…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a nudge in your chart unlock Life-Saving genetic clues?
Knowledge-focused Recruiting nowThis study tests whether simple reminders—called nudges—sent to doctors and patients can increase the use of genetic testing for people with certain conditions like Parkinson's disease, ALS, or heart problems. The trial will compare different ways of prompting genetic testing, su…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Tiny coil placed inside nose could help surgeons spot hidden brain tumors
Knowledge-focused Recruiting nowThis study tests a small MRI coil placed inside the sphenoid sinus during pituitary tumor surgery. The goal is to see if it can provide clearer images of tiny tumors that standard MRI often misses. About 70 adults with pituitary tumors will take part. The coil is inserted through…
Phase: NA • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Cured of cushing as a kid? scientists want to track your health for years
Knowledge-focused Recruiting nowThis study looks at the long-term health of people who were cured of Cushing disease before age 21. Researchers want to understand how past high cortisol levels affect the body and mind years later. Participants will complete surveys and have check-ups every 5 years. The goal is …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Quick fingerprick test could curb infection spread in rural west virginia
Knowledge-focused Recruiting nowThis study looks at whether a rapid fingerstick test that gives results in 10-20 minutes can help more people get screened for HIV, hepatitis C, and syphilis during mobile clinic visits. About 200 patients of the WVU Street Medicine team can choose the rapid test, a traditional b…
Sponsor: West Virginia University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Do Younger-Age pancreatic tumors behave differently? a new study digs in
Knowledge-focused Recruiting nowThis study looks back at medical records from 600 people to compare pancreatic neuroendocrine tumors (PanNETs) that appear at a younger age versus those that appear later in life. Researchers want to see if these two groups have different risk factors, tumor features, metabolic c…
Sponsor: Qilu Hospital of Shandong University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive global study tracks Durvalumab's Real-World impact on liver cancers
Knowledge-focused Recruiting nowThis study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive study aims to unlock genetic secrets of childhood hormone disorders
Knowledge-focused Recruiting nowThis study enrolls up to 15,000 children with known or suspected endocrine or metabolic disorders, along with their family members. Researchers will collect medical records, blood, saliva, and other samples to identify genetic changes linked to these conditions. The goal is to be…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
No treatment, just samples: new study aims to understand cancer immunity
Knowledge-focused Recruiting nowThis study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Major study launches to uncover hidden health risks in androgen insensitivity
Knowledge-focused Recruiting nowThis study follows 650 people aged 8 to 99 with androgen insensitivity syndrome (AIS) to better understand their long-term health. Researchers will track hormones, bone density, heart health, metabolism, and tumor risk through regular check-ups and scans. No treatments are being …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Small study to uncover how exercise changes Liver's sugar output in diabetes
Knowledge-focused Recruiting nowThis study looks at how exercise changes the amount of sugar the liver makes in people with type 2 diabetes and fatty liver disease. Researchers will measure liver sugar production during rest and exercise in 12 adults aged 25-55. The goal is to better understand how exercise hel…
Phase: NA • Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Your genes may decide if metformin works for you
Knowledge-focused Recruiting nowThis study is looking at whether a specific genetic variation, called SLC16A11, influences how well the common diabetes drug metformin lowers blood sugar. Adults with type 2 diabetes will be grouped by whether they carry this gene variant and will take extended-release metformin …
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Mapping lung cancer genes to unlock future treatments
Knowledge-focused Recruiting nowThis study analyzes tumor tissue from 797 people with relapsed small cell lung cancer to identify genetic subtypes. No drugs are tested here. Instead, the results may help match patients to future targeted therapy trials. Participants must have had prior platinum-based chemothera…
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New drug AZD4248 tested for kidney disease in first human trials
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called AZD4248 in healthy volunteers and people with chronic kidney disease and type 2 diabetes. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Liver disease study aims to map recovery and organ failure over 6 months
Knowledge-focused Recruiting nowThis study will follow 100 adults with chronic liver disease who are hospitalized for sudden worsening of their condition. Researchers will track organ failure, recovery, and whether patients need a liver transplant or die within 6 months. The goal is to better understand how the…
Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Wheat sensitivity linked to fatty liver? a new study investigates
Knowledge-focused Recruiting nowThis study looks at whether people with non-celiac wheat sensitivity (NCWS) have a higher chance of having fatty liver or liver scarring. Researchers will compare liver health in people with NCWS to those with irritable bowel syndrome, functional dyspepsia, and celiac disease. Th…
Sponsor: University of Palermo • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can diabetes disrupt the Brain-Heart link?
Knowledge-focused Recruiting nowThis study looks at how metabolic problems in type 2 diabetes might affect the way the brain and heart communicate. Researchers will measure brain activity, heart rhythm, physical fitness, and mental well-being in about 46 adults with type 2 diabetes. The goal is to see if these …
Sponsor: Hacettepe University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Could a simple estrogen pill reveal hidden oxytocin deficiency?
Knowledge-focused Recruiting nowThis study is testing whether taking estrogen pills (estradiol valerate or ethinylestradiol) can safely trigger the release of oxytocin, a hormone important for social bonding and childbirth. Researchers will measure oxytocin levels in 28 healthy volunteers and patients with AVP …
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
HER2 test showdown: which lab method is best for chinese cancer patients?
Knowledge-focused Recruiting nowThis study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Liver health may change how body handles inhaled lung drug
Knowledge-focused Recruiting nowThis phase 1 trial investigates how mild, moderate, and severe liver impairment affects the way the body processes a single inhaled dose of treprostinil palmitil, a drug used for certain lung conditions. The study enrolls about 30 adults with varying levels of liver function and …
Phase: PHASE1 • Sponsor: Insmed Incorporated • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Hidden thyroid cancers may be more common in Graves' disease than thought
Knowledge-focused Recruiting nowThis study looks at how often thyroid cancer is found by accident when people with Graves' disease have their thyroid gland removed. Researchers will track 280 adults having this surgery and examine the removed tissue carefully for any cancer, including tiny microcarcinomas. They…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gene hunt in newly diagnosed type 1 diabetes adults
Knowledge-focused Recruiting nowThis study is for adults aged 18 to 55 who were diagnosed with type 1 diabetes within the last 6 months. Researchers want to see how many of them carry a specific gene called HLA-DRB1*04:01. Participants will provide a blood sample or cheek swab for genetic testing. The goal is t…
Sponsor: GentiBio, Inc • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New study checks if cancer drug olutasidenib changes how other medicines work
Knowledge-focused Recruiting nowThis study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Massive study aims to unlock genetic secrets of pediatric liver tumors
Knowledge-focused Recruiting nowThis study is collecting genetic and molecular data from up to 1,600 children with liver cancer and their families. Researchers will analyze DNA, gene activity, and immune cells to better understand what drives these rare tumors. The goal is to improve how these cancers are class…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Finger-Prick test aims to uncover hidden hepatitis c cases
Knowledge-focused Recruiting nowThis study is testing whether a quick finger-stick test can help find more people with hepatitis C and get them into treatment. About 60,000 adults at risk for hepatitis C will take the test at clinics, shelters, or prisons. The study itself does not provide treatment, but will c…
Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New model could make thyroid surgery safer and more predictable
Knowledge-focused Recruiting nowThis study aims to improve a prediction model that helps doctors know how difficult a less invasive thyroid surgery might be. Researchers will observe 300 people with thyroid cancer or benign nodules to see which factors, like age, weight, and tumor size, affect surgery difficult…
Sponsor: Shanghai 6th People's Hospital • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Cancer drug pralsetinib may change how the body processes other medications
Knowledge-focused Recruiting nowThis study looks at how the cancer drug pralsetinib (Gavreto) affects the way the body breaks down other drugs and hormones. Researchers will give a cocktail of common medications and a hormone-based contraceptive to people with advanced solid tumors, then measure how pralsetinib…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Building a better understanding of Low-Grade ovarian cancer
Knowledge-focused Recruiting nowThis study gathers medical records and leftover tissue samples from up to 2,000 people with low-grade ovarian or peritoneal tumors. The goal is to create a detailed database that helps researchers learn more about these rare cancers and how they are treated. No new drugs or proce…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could a common diabetes drug unlock the mystery of insulin failure?
Knowledge-focused Recruiting nowThis study investigates whether a key channel in insulin-producing cells becomes less active as type 2 diabetes progresses. Researchers will give a single 10 mg dose of glipizide, a drug that blocks this channel, to people with and without type 2 diabetes and measure their insuli…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
PCOS study hunts for genetic clues behind severe insulin resistance
Knowledge-focused Recruiting nowThis study aims to find out whether some women diagnosed with polycystic ovary syndrome (PCOS) actually have a rare genetic condition causing severe insulin resistance. Researchers will compare 25 women with a known LMNA gene mutation (linked to lipodystrophy) to 50 women with cl…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists hunt for genetic clues to biliary atresia, top cause of liver transplants in kids
Knowledge-focused Recruiting nowThis study aims to uncover the genetic and developmental causes of biliary atresia, a rare condition that leads to liver failure in newborns and accounts for half of all childhood liver transplants worldwide. Researchers will analyze DNA from 1,100 children who have had or need a…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists launch Largest-Ever study of rare bladder and genital cancers
Knowledge-focused Recruiting nowThis study follows 1,100 adults with rare urinary tract cancers, such as unusual bladder, kidney, testicular, or penile cancers. Researchers will collect medical records, blood and tumor samples, and imaging over many years to understand how these cancers grow and respond to trea…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Diabetes and vitamin c loss: scientists launch major study to solve the mystery
Knowledge-focused Recruiting nowThis study aims to find out why people with diabetes often have lower vitamin C levels in their blood. Researchers will measure vitamin C in blood, urine, and cells from 5,000 adults with and without diabetes. They will also look at genes that control vitamin C transport. The goa…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Worldwide data pool could pave the way for mitochondrial disease trials
Knowledge-focused Recruiting nowThis study creates a global registry for people with mitochondrial disorders—rare diseases that affect energy production in cells. By collecting health data from 6,000 participants worldwide, researchers aim to understand how these diseases progress and identify the best ways to …
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists collect tissue to unlock lung cancer secrets
Knowledge-focused Recruiting nowThis study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Taste bud stem cells could be key to diabetes cure
Knowledge-focused Recruiting nowThis study explores whether stem cells from taste buds can be turned into insulin-making cells. Researchers will take tiny tissue samples from the tongues of 250 healthy adults to isolate and grow these stem cells in a lab. The goal is to see if this is possible in humans, which …
Sponsor: National Institute on Aging (NIA) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New study checks if hypoparathyroidism drug passes into breast milk
Knowledge-focused Recruiting nowThis study looks at how much of the drug palopegteriparatide (YORVIPATH) gets into breast milk. It involves 10 women with hypoparathyroidism who are already taking the drug and breastfeeding. Researchers will collect milk samples to measure drug levels, helping understand safety …
Sponsor: Ascendis Pharma A/S • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New study to reveal hidden pancreatic issues in alagille syndrome patients after transplant
Knowledge-focused Recruiting nowThis study aims to find out how often exocrine pancreatic insufficiency (EPI) occurs in people with Alagille syndrome who have had a liver transplant. About 30 participants aged 7 to 50 will eat a high-fat diet and collect stool samples for lab testing. The results will help doct…
Sponsor: Digestive Care, Inc. • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
18-Year study to uncover roots of childhood obesity and diabetes
Knowledge-focused Recruiting nowThis study follows 1,500 pregnant women and their children for up to 18 years to understand how a mother's health, lifestyle, and environment affect her child's growth and risk for obesity, diabetes, and fatty liver. Mothers attend visits during pregnancy and after birth, while c…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Could immune cells in fat hold the key to Obesity-Related disease?
Knowledge-focused Recruiting nowThis study is investigating how immune cells called macrophages in fat tissue handle fat and influence metabolism. Researchers will compare people with obesity and related metabolic issues to lean individuals, using imaging, blood tests, and tissue biopsies. The goal is to unders…
Sponsor: Bettina Mittendorfer • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a simple blood test spot lymphoma earlier?
Knowledge-focused Recruiting nowThis study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor can…
Sponsor: Natera, Inc. • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Rare cancer study: does surgery help patients live longer?
Knowledge-focused Recruiting nowThis study looks at people with a rare and aggressive type of esophageal cancer that hasn't spread. It compares those who had surgery (with or without other treatments) to those who had non-surgical treatments like chemotherapy and radiation. The goal is to see which approach hel…
Sponsor: yi shen • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Why are some women with turner syndrome fertile? scientists launch genetic hunt
Knowledge-focused Recruiting nowThis study aims to create a large genetic database of people with Turner syndrome, a rare condition where a person is missing all or part of an X chromosome. Researchers want to compare the genes of women with Turner syndrome who are fertile with those who are not. Up to 500 part…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Massive study aims to unlock mysteries of teen gynecologic disorders
Knowledge-focused Recruiting nowThis study is collecting medical data, blood, saliva, and tissue samples from up to 11,000 children, teens, and adults with known or suspected gynecologic conditions. The goal is to create a large database to better understand these conditions, including disorders of sex developm…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Liver function may change how new lung drug works
Knowledge-focused Recruiting nowThis study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC